Search

Start Over Keyword Pyrimidines

  • Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

    Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
    Authors:Antoine N Saliba, Mayo ClinicScott H Kaufmann, Mayo ClinicEytan M Stein, Memorial Sloan-Kettering Cancer CenterPtapti A Patel, UT Southwestern Medical SchoolMaria R Baer, University of Maryland Marlene and Stewart Greenebaum Cancer CenterWendy Stock, Section of Hematology Oncology, The University of ChicagoMichael Deininger, University of Utah School of MedicineWilliam Blum, Emory UniversityGary J Schiller, David Geffen School of Medicine at UCLARebecca L Olin, University of California, San FranciscoMark R Litzow, Mayo ClinicTara L Lin, University of Kansas Medical CenterBrian J Ball, City of Hope National Med CenterMichael M Boyiadzis, University of PittsburghElie Traer, Oregon Health & Science UniversityOlatoyosi Odenike, University of ChicagoMartha Arellano, Emory UniversityAlison Walker, The Ohio State UniversityVu H Duong, University of Maryland Marlene and Stewart Greenebaum Cancer CenterTibor Kovacsovics, University of Utah School of MedicineRobbert H Collins, UT Southwestern Medical SchoolAbigail B Shoben, The Ohio State UniversityNyla A Heerema, The Ohio State UniversityMatthew C Foster, The University of North Carolina at Chapel HillKevin L Peterson, Mayo ClinicPaula A Schneider, Mayo ClinicMolly Martycz, The Ohio State UniversityTheophilus J Gana, Biopharmatech Consulting, IncLeonard Rosenberg, Sociedad de Lucha Contra la Leucemia y el LinfomaSonja Marcus, Sociedad de Lucha Contra la Leucemia y el LinfomaAshley O Yocum, Sociedad de Lucha Contra la Leucemia y el LinfomaTimothy Chen, The Ohio State UniversityMona Stefanos, The Ohio State UniversityAlice S Mims, The Ohio State UniversityUma Borate, The Ohio State UniversityAmy Burd, Sociedad de Lucha Contra la Leucemia y el LinfomaBrian J Druker, Oregon Health & Science UniversityRoss L Levine, Memorial Sloan-Kettering Cancer CenterJohn C Byrd, University of CincinnatiJames M Foran, Mayo Clinic in Jacksonville, Florida
    Date:2023
    Publisher:The American Society of Hematology
    Publication Version:Final Published Version
    License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

  • Inhibition of H3K27me3 Demethylases Promotes Plasmablast Formation

    Inhibition of H3K27me3 Demethylases Promotes Plasmablast Formation
    Authors:Anna K Kania, Emory UniversityMuyao Guo, Emory UniversityChristopher Scharer, Emory UniversityJeremy Boss, Emory University
    Date:2021
    Publisher:The American Association of Immunologists, Inc
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International

  • A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

    A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
    Authors:Keith W Pratz, University of PennsylvaniaJason Kaplan, Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityMoshe Levy, Baylor University Medical CenterDale Bixby, University of Michigan Rogel Cancer CenterPatrick W Burke, University of Michigan Rogel Cancer CenterHarry Erba, Duke UniversityTrisha M Wise-Draper, University of CincinnatiGail J Roboz, Weill Cornell Medical CollegeNikolaos Papadantonakis, Emory UniversityTrivikram Rajkhowa, The Sidney Kimmel Comprehensive Cancer CenterDaniela Hernandez, The Sidney Kimmel Comprehensive Cancer CenterIwona Dobler, Takeda Development Center Americas Inc.Richard C Gregory, Takeda Development Center Americas Inc.Cheryl Li, Takeda Development Center Americas Inc.Shining Wang, Takeda Development Center Americas Inc.Kate Stumpo, Takeda Development Center Americas Inc.Karuppa Kannan, Takeda Development Center Americas Inc.Harry Miao, Takeda Development Center Americas Inc.Mark Levis, The Sidney Kimmel Comprehensive Cancer Center
    Date:2023
    Publisher:Ferrata Storti Foundation
    Publication Version:Final Published Version
    License:Creative Commons Attribution-NonCommercial 4.0 International

  • A pharmacodynamic analysis of choroidal neovascularization in a porcine model using three targeted drugs

    A pharmacodynamic analysis of choroidal neovascularization in a porcine model using three targeted drugs
    Authors:Jeffrey Tran, Emory UniversityCaroline Craven, Emory UniversityKathy Wabner, Emory UniversityJenn Schmit, Emory UniversityBrock Matter, University of ColoradoUday Kompella, University of ColoradoHans Grossniklaus, Emory UniversityTimothy Olsen, Emory University
    Date:2017
    Publisher:Association for Research in Vision and Ophthalmology (ARVO)
    Publication Version:Final Published Version
    License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

  • A novel RNA molecular signature for activation of 2'-5' oligoadenylate synthetase-1

    A novel RNA molecular signature for activation of 2'-5' oligoadenylate synthetase-1
    Authors:Virginia K. Vachon, Emory UniversityBrenda M. Calderon, Emory UniversityGraeme L Conn, Emory University
    Date:2014
    Publisher:Oxford University Press
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International